How well do angiogenesis inhibitors work? Biomarkers of response prove elusive

J Natl Cancer Inst. 2009 Jun 16;101(12):846-7. doi: 10.1093/jnci/djp171. Epub 2009 Jun 9.
No abstract available

Publication types

  • News

MeSH terms

  • Angiogenesis Inhibitors / pharmacology*
  • Angiogenesis Inhibitors / therapeutic use
  • Animals
  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates / pharmacology
  • Bevacizumab
  • Biomarkers, Tumor / metabolism*
  • Cytokines / metabolism*
  • Disease-Free Survival
  • Endothelial Cells* / drug effects
  • Humans
  • Indoles / pharmacology
  • Neoplasms / blood supply
  • Neoplasms / drug therapy*
  • Neoplasms / metabolism*
  • Neoplasms / mortality
  • Neoplasms / pathology
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / pharmacology
  • Pyrroles / pharmacology
  • Sorafenib
  • Sunitinib
  • Survival Analysis
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Benzenesulfonates
  • Biomarkers, Tumor
  • Cytokines
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Vascular Endothelial Growth Factor A
  • Niacinamide
  • Bevacizumab
  • Sorafenib
  • Sunitinib